Registry for Hypertrophic Cardiomyopathy in Taiwan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to evaluate the clinical, genetic, and biochemical features of hypertrophic cardiomyopathy (HCM) and related rare diseases like Fabry disease in Taiwan. It will systematically assess the prevalence of HCM within the Taiwanese population and identify specific 'red-flag' signs for Fabry disease. The study will include adult patients with left ventricular hypertrophy (LVH) and will gather data through echocardiograms and cardiac MRI. The goal is to improve diagnosis and treatment strategies for HCM and related conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Presence of left ventricular hypertrophy (LVH) on echo/CMRI:
2. maximal interventricular septal (IVST) and/or posterior wall thickness (PWT) ≥13 mm,
3. apical wall thickness ≥15 mm or a ratio of apical to basal LV wall thickness of ≥ 1.3 at end-diastole, OR
4. maximal LV wall thickness ≥ 15mm of ANY OTHER PART
5. Male and female adult age ≥ 20 year-old
6. Patients willing to comply with and sign the informed consent

Exclusion Criteria:

1. Patients refuse or unable to give informed consent
2. Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the program
3. Co-arctation of the aorta, severe aortic stenosis, or severe LV pressure overload
4. Athletic heart
5. Non-compaction cardiomyopathy

Where it's running

• Far Eastern Memorial Hospital
  New Taipei City, Taiwan Recruiting

Study contacts

• Study coordinator: Yen-Wen Wu, PhD
• Email: wuyw0502@gmail.com
• Phone: +886289667000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy in Chinese adults

  This project will test how well mavacamten works for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy when used in everyday clinical care.

  Recruiting at 10 sites Bristol-Myers Squibb · Beijing, Beijing Municipality and 14 other locations · NCT07361289

• Long-term safety of HRS-1893 for people with hypertrophic cardiomyopathy

  This study tests the long-term safety of the oral drug HRS-1893 in people with hypertrophic cardiomyopathy who previously received HRS-1893.

  Recruiting Phase 2 Shandong Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07021963

• Study of heart conditions using advanced imaging techniques

  This study is trying to find out what causes different heart conditions in Hispanic and African American people in the Bronx by using advanced imaging techniques.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06610019

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

• Comparing inspiratory muscle training and Baduanjin exercises for heart health

  This study tests whether breathing exercises or a special exercise program can help people with hypertrophic cardiomyopathy improve their lung function, exercise ability, and overall quality of life.

  Recruiting Istanbul University - Cerrahpasa · Istanbul · NCT06490250

• Using advanced imaging to evaluate heart muscle scarring in various heart conditions

  This study is testing a new imaging method to see how heart scarring changes over time in people with certain heart conditions.

  Recruiting University of Edinburgh · Edinburgh, Scotland · NCT06409585

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.